title: Viral hepatitis and inflammatory bowel disease.
abstract: Viral hepatitis is common worldwide and in the United States. Inflammatory bowel disease (IBD) patients with chronic hepatitis B virus (HBV) with active disease (elevated alanine aminotransferase level and viral replication) should receive HBV treatment. HBV reactivation is associated with significant morbidity and mortality in patients receiving immunosuppression. IBD patients may require long-term immunosuppression, and therefore should be considered candidates for vaccination against new HBV infection as well as prophylaxis against HBV reactivation prior to immunosuppressive therapy. Tumor necrosis factor alpha antagonists and immunomodulators appear compatible with use in IBD patients with HCV, although prednisone may increase viral replication. HCV treatment with peg-interferon and ribavirin may exacerbate gastrointestinal symptoms, and therefore the decision to treat HCV needs to be individualized. Management of IBD patients with viral hepatitis is addressed in this review.
authors.affiliation: Baylor College of Medicine, Houston, Texas, USA.
authors.forename: Jason K
authors.initials: JK
authors.lastname: Hou
authors.forename: Fernando
authors.initials: F
authors.lastname: Velayos
authors.forename: Norah
authors.initials: N
authors.lastname: Terrault
authors.forename: Uma
authors.initials: U
authors.lastname: Mahadevan
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006525:Hepatitis, Viral, Human / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D017410:Practice Guidelines as Topic; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D014761:Viral Hepatitis Vaccines; D012254:Ribavirin; D007372:Interferons; D000410:Alanine Transaminase; D011241:Prednisone